TMDX TransMedics Group, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1756262 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY28.5%
TTM net income YoY57.4%
TTM EPS YoY48.0%
Revenue 3-yr CAGR56.0%
Net income 3-yr CAGR—
Margins
Gross margin58.6%
Operating margin11.9%
Net margin19.9%
FCF margin6.1%
EBITDA margin17.4%
Returns
ROE31.9%
ROA11.7%
ROIC (approx.)—
Asset turnover0.59x
Leverage & solvency
Liabilities / assets63.7%
Debt / equity0.00x
Current ratio4.53x
Interest coverage3.46x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio2.6%
Payout ratio—
Capex / revenue9.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $203.00M | $189.95M | $173.93M | $160.76M | $143.82M | $157.37M | $143.54M | $121.62M |
| Cost of revenue | $84.35M | $76.75M | $72.77M | $67.35M | $59.25M | $60.78M | $55.31M | $49.61M |
| Gross profit | $118.66M | $113.20M | $101.16M | $93.41M | $84.58M | $96.59M | $88.23M | $72.01M |
| R&D expense | $29.18M | $31.63M | $24.88M | $20.70M | $15.26M | $15.93M | $17.16M | $16.46M |
| SG&A expense | $61.33M | $57.83M | $62.98M | $51.44M | $46.02M | $44.09M | $43.62M | $46.91M |
| Operating income | $28.14M | $23.74M | $13.30M | $21.27M | $23.30M | $36.57M | $27.44M | $8.64M |
| Interest expense | $7.27M | $7.22M | $7.17M | $3.35M | $3.49M | $3.48M | $3.46M | $3.57M |
| Pretax income | $24.10M | $19.41M | $8.48M | $21.63M | $23.03M | $36.18M | $26.68M | $6.99M |
| Income tax | $7.03M | $4.72M | $1.17M | -$83.75M | -$1.29M | $1.27M | $994,000 | $132,000 |
| Net income | $17.07M | $14.68M | $7.32M | $105.38M | $24.32M | $34.91M | $25.68M | $6.86M |
| EBITDA | $38.98M | $33.98M | $25.16M | $28.74M | $30.15M | $43.30M | $33.58M | $14.32M |
| EPS (basic) | 0.49 | 0.42 | 0.21 | — | 0.71 | 1.03 | 0.76 | — |
| EPS (diluted) | 0.46 | 0.41 | 0.20 | — | 0.66 | 0.92 | 0.70 | — |
| Weighted avg. shares (diluted) | 40.83M | 40.71M | 36.19M | — | 40.75M | 40.56M | 39.91M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $511.40M | $491.11M | $480.18M | $488.87M | $466.67M | $401.07M | $310.64M | $337.15M |
| Receivables | $114.94M | $104.14M | $90.73M | $84.28M | $80.70M | $104.85M | $142.03M | $97.72M |
| Inventory | $58.37M | $54.14M | $49.89M | $48.88M | $44.51M | $38.87M | $43.38M | $46.55M |
| Current assets | $692.46M | $651.12M | $619.28M | $637.78M | $613.00M | $558.13M | $505.92M | $497.22M |
| PP&E, net | $376.49M | $365.30M | $361.57M | $327.66M | $313.02M | $312.25M | $311.24M | $285.97M |
| Goodwill | $18.02M | $11.55M | $11.55M | $11.55M | $11.55M | $11.55M | $11.55M | $11.55M |
| Intangibles | $2.81M | $0 | $0 | $1.95M | $2.00M | $2.05M | $2.10M | $2.15M |
| Total assets | $1.52B | $1.46B | $1.43B | $1.07B | $946.03M | $890.52M | $837.53M | $804.08M |
| Current liabilities | $152.86M | $98.28M | $91.92M | $89.31M | $79.72M | $56.62M | $55.60M | $59.91M |
| Short-term debt | $54.82M | $20.00M | $15.00M | $10.00M | $5.00M | — | — | — |
| Total liabilities | $967.23M | $946.34M | $940.81M | $595.27M | $590.83M | $572.42M | $571.22M | $575.47M |
| Shareholders' equity | $550.71M | $518.05M | $494.01M | $473.10M | $355.20M | $318.10M | $266.31M | $228.60M |
| Shares outstanding | 34.72M | 34.63M | 34.55M | 34.27M | 34.14M | 34.04M | 33.83M | 33.62M |
| Cash flow statement | ||||||||
| Operating cash flow | $36.00M | $17.31M | $24.53M | $34.51M | $69.57M | $91.61M | -$2.85M | $19.66M |
| Capital expenditure | $8.40M | $7.09M | $36.66M | $15.51M | $7.62M | $9.07M | $27.04M | $13.61M |
| Free cash flow | $27.60M | $10.22M | -$12.12M | $19.00M | $61.95M | $82.53M | -$29.89M | $6.06M |
| Investing cash flow | -$13.71M | -$7.09M | -$36.66M | -$15.51M | -$7.62M | -$9.07M | -$27.04M | -$13.61M |
| Financing cash flow | -$1.92M | $970,000 | $3.76M | $3.10M | $3.64M | $7.09M | $3.03M | $1.19M |
| Depreciation & amortization | $10.84M | $10.24M | $11.86M | $7.47M | $6.85M | $6.73M | $6.14M | $5.68M |
| Stock-based compensation | $12.60M | $8.61M | $9.95M | $9.39M | $9.14M | $9.37M | $8.96M | $10.77M |
Free plan shows the latest 8 periods; Pro shows all 36 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.